• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化和非特异性间质性肺炎患者支气管肺泡灌洗液中钙粒蛋白 B 和 KL-6。

Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP.

机构信息

Respiratory Diseases and Lung Transplantation Unit, AOUS - Department of Medical, Surgical and Neurological Sciences, University of Siena, Viale Bracci, 16 -, 53100, Siena, Italy.

Diagnostic Imaging Unit, AOUS - Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.

出版信息

Inflammation. 2019 Apr;42(2):463-470. doi: 10.1007/s10753-018-00955-2.

DOI:10.1007/s10753-018-00955-2
PMID:30680696
Abstract

Idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) are the most frequent idiopathic interstitial pneumonias. The aim of this study was to evaluate concentrations of calgranulin B and Krebs von den Lungen 6 (KL-6) in bronchoalveolar lavage (BAL) fluid of patients with IPF and idiopathic NSIP (i-NSIP) with fibrotic pattern. Thirty patients with IPF (68.73 ± 8.63 years), 30 with i-NSIP (68.33 ± 7.45 years), and healthy controls were included in the study. Calgranulin B and KL-6 both proved to be significantly higher in BAL of IPF and i-NSIP patients than in healthy controls (p < 0.05). Calgranulin B showed several significant correlations with functional parameters (oxygen demand at rest, 6-min walking test (6MWT), and PFTs); KL-6 was correlated with oxygen demand at rest and during 6MWT. Patients with higher concentrations of both biomarkers (> 75th percentile) had more advanced disease with lower values of FEV1%, FVC%, RV%, TLC%, DLCO% of predicted, distance walked in 6MWT, and BAL neutrophil percentage. Calgranulin B and KL-6 in BAL proved to be reliable biomarkers of IPF and i-NSIP and to have prognostic meaning, discriminating severe and advanced patients. The combination of the two biomarkers can facilitate the stratification of severity.

摘要

特发性肺纤维化(IPF)和非特异性间质性肺炎(NSIP)是最常见的特发性间质性肺炎。本研究旨在评估特发性纤维化型 NSIP(i-NSIP)和 IPF 患者支气管肺泡灌洗液(BAL)中钙粒蛋白 B 和 KL-6 的浓度。本研究纳入 30 例 IPF 患者(68.73±8.63 岁)、30 例 i-NSIP 患者(68.33±7.45 岁)和健康对照组。结果显示,BAL 中钙粒蛋白 B 和 KL-6 在 IPF 和 i-NSIP 患者中均显著高于健康对照组(p<0.05)。钙粒蛋白 B 与功能参数(静息氧需求、6 分钟步行试验(6MWT)和 PFTs)有显著相关性;KL-6 与静息和 6MWT 期间的氧需求相关。两种生物标志物浓度较高(>75 百分位)的患者疾病更为严重,FEV1%、FVC%、RV%、TLC%、DLCO%预测值、6MWT 步行距离和 BAL 中性粒细胞百分比均较低。BAL 中的钙粒蛋白 B 和 KL-6 被证明是 IPF 和 i-NSIP 的可靠生物标志物,具有预后意义,可区分严重和晚期患者。两种生物标志物的联合使用可以促进严重程度的分层。

相似文献

1
Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP.特发性肺纤维化和非特异性间质性肺炎患者支气管肺泡灌洗液中钙粒蛋白 B 和 KL-6。
Inflammation. 2019 Apr;42(2):463-470. doi: 10.1007/s10753-018-00955-2.
2
S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.BALF 中的 S100A9 是特发性肺纤维化的候选生物标志物。
Respir Med. 2012 Apr;106(4):571-80. doi: 10.1016/j.rmed.2011.12.010. Epub 2011 Dec 30.
3
Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis?钙粒蛋白 B(S100A9/MRP14):特发性肺纤维化的关键分子?
Inflammation. 2011 Apr;34(2):85-91. doi: 10.1007/s10753-010-9210-7.
4
Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.评估随时间变化的克雷布斯-冯-登-伦根-6(Krebs von den Lungen-6)和表面活性蛋白-D血清水平变化,作为特发性纤维化非特异性间质性肺炎的重要生物标志物。
Respir Investig. 2019 Sep;57(5):422-429. doi: 10.1016/j.resinv.2019.03.006. Epub 2019 Apr 16.
5
Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.特发性间质性肺炎血清学标志物 KL-6、SP-A、SP-D、CCL2 和 CXCL13 的诊断效能评价。
Respiration. 2019;98(6):534-545. doi: 10.1159/000503689. Epub 2019 Oct 30.
6
[The Role of Bronchoalveolar Lavage in the Diagnosis of Idiopathic Pulmonary Fibrosis: An Investigation of the Relevance of the Protein Content].[支气管肺泡灌洗在特发性肺纤维化诊断中的作用:蛋白质含量相关性研究]
Pneumologie. 2016 Jul;70(7):435-41. doi: 10.1055/s-0042-107267. Epub 2016 May 24.
7
[The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].[KL-6在不同弥漫性间质性肺疾病患者血清和支气管肺泡灌洗液中的表达及临床作用]
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Feb;39(2):93-7. doi: 10.3760/cma.j.issn.1001-0939.2016.02.004.
8
Innate immunity alterations in idiopathic interstitial pneumonias and rheumatoid arthritis-associated interstitial lung diseases.特发性间质性肺炎和类风湿关节炎相关间质性肺疾病中的先天性免疫改变。
Immunol Lett. 2015 Feb;163(2):179-86. doi: 10.1016/j.imlet.2014.12.004. Epub 2014 Dec 23.
9
MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases.MRP14 在纤维化性间质性肺疾病的支气管肺泡灌洗液中升高。
Clin Exp Immunol. 2010 Aug;161(2):342-7. doi: 10.1111/j.1365-2249.2010.04181.x. Epub 2010 Jun 9.
10
Prognostic performance of Krebs von den Lungen-6, surfactant protein A, surfactant protein D levels in the serum and bronchoalveolar lavage fluid in chronic fibrosing interstitial pneumonia: a retrospective study.血清和支气管肺泡灌洗液中 Krebs von den Lungen-6、表面活性剂蛋白 A、表面活性剂蛋白 D 水平对慢性纤维化间质性肺炎的预后价值:一项回顾性研究。
BMC Pulm Med. 2024 Aug 22;24(1):404. doi: 10.1186/s12890-024-03224-1.

引用本文的文献

1
Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction.性别差异是特发性肺纤维化患者在抗纤维化治疗减量后5年生存率的主要影响因素。
Life (Basel). 2025 Jan 16;15(1):106. doi: 10.3390/life15010106.
2
Korean Guidelines for Diagnosis and Management of Idiopathic Nonspecific Interstitial Pneumonia.韩国特发性非特异性间质性肺炎诊断与管理指南
Tuberc Respir Dis (Seoul). 2025 Apr;88(2):237-246. doi: 10.4046/trd.2024.0168. Epub 2025 Jan 6.
3
KL‑6, ET‑1 and S100A9 levels in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea.

本文引用的文献

1
Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者血清KL-6连续检测的预后价值
Respir Investig. 2017 Jan;55(1):16-23. doi: 10.1016/j.resinv.2016.09.003. Epub 2016 Nov 9.
2
Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.循环中基质金属蛋白酶-7、CC趋化因子配体18、KL-6、表面活性蛋白A和表面活性蛋白D作为特发性肺纤维化疾病标志物的比较研究
Dis Markers. 2016;2016:4759040. doi: 10.1155/2016/4759040. Epub 2016 May 17.
3
MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis.
特发性肺纤维化和阻塞性睡眠呼吸暂停患者的KL-6、ET-1和S100A9水平
Exp Ther Med. 2024 Nov 18;29(1):16. doi: 10.3892/etm.2024.12766. eCollection 2025 Jan.
4
The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis.成纤维细胞活化蛋白α作为肺纤维化的生物标志物。
Front Med (Lausanne). 2024 Sep 19;11:1393778. doi: 10.3389/fmed.2024.1393778. eCollection 2024.
5
A Pilot HRCT Follow-Up Study to Test the Feasibility of Predictive Efficacy of Serum Periostin in Idiopathic Pulmonary Fibrosis.一项测试血清骨膜蛋白对特发性肺纤维化预测疗效可行性的HRCT初步随访研究。
J Inflamm Res. 2024 Sep 25;17:6729-6742. doi: 10.2147/JIR.S458428. eCollection 2024.
6
Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction.特发性肺纤维化中的生物标志物:当前见解与未来方向。
Chin Med J Pulm Crit Care Med. 2024 Jun;2(2):72-79. doi: 10.1016/j.pccm.2024.04.003. Epub 2024 Jun 14.
7
High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis.高 S100A9 水平预示着不良预后,S100A9 抑制剂帕奎莫德是治疗特发性肺纤维化的候选药物。
BMJ Open Respir Res. 2024 Feb 20;11(1):e001803. doi: 10.1136/bmjresp-2023-001803.
8
S100 Calcium-Binding Protein A9, a Potential Novel Diagnostic Biomarker for Idiopathic Pulmonary Fibrosis.S100 钙结合蛋白 A9,特发性肺纤维化的潜在新型诊断生物标志物。
J Korean Med Sci. 2024 Jan 8;39(1):e13. doi: 10.3346/jkms.2024.39.e13.
9
Molecular and Genetic Biomarkers in Idiopathic Pulmonary Fibrosis: Where Are We Now?特发性肺纤维化中的分子和遗传生物标志物:我们目前的进展如何?
Biomedicines. 2023 Oct 16;11(10):2796. doi: 10.3390/biomedicines11102796.
10
Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis.蛋白质组学适体分析揭示了与系统性硬化症疾病机制和表型相关的血清生物标志物。
Front Immunol. 2023 Sep 11;14:1246777. doi: 10.3389/fimmu.2023.1246777. eCollection 2023.
MUC1基因多态性与肺泡蛋白沉积症患者的血清KL-6水平及肺功能障碍相关。
Orphanet J Rare Dis. 2016 Apr 23;11:48. doi: 10.1186/s13023-016-0430-2.
4
Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells.肿瘤浸润性单核细胞/巨噬细胞通过上调癌细胞中S100A8和S100A9的表达促进肿瘤侵袭和迁移。
Oncogene. 2016 Nov 3;35(44):5735-5745. doi: 10.1038/onc.2016.107. Epub 2016 Apr 18.
5
[The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].[KL-6在不同弥漫性间质性肺疾病患者血清和支气管肺泡灌洗液中的表达及临床作用]
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Feb;39(2):93-7. doi: 10.3760/cma.j.issn.1001-0939.2016.02.004.
6
Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis.特发性肺纤维化评估与管理中的生物标志物
Curr Top Med Chem. 2016;16(14):1587-98. doi: 10.2174/1568026616666150930120959.
7
Nonspecific interstitial pneumonia: survival is influenced by the underlying cause.非特异性间质性肺炎:存活率受基础病因影响。
Eur Respir J. 2015 Mar;45(3):746-55. doi: 10.1183/09031936.00148613. Epub 2014 Dec 23.
8
An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease.一个官方的欧洲呼吸学会/美国胸科学会技术标准:慢性呼吸疾病的现场行走测试。
Eur Respir J. 2014 Dec;44(6):1428-46. doi: 10.1183/09031936.00150314. Epub 2014 Oct 30.
9
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis.基线KL-6可预测特发性肺纤维化急性加重风险增加。
Respir Med. 2014 Jul;108(7):1031-9. doi: 10.1016/j.rmed.2014.04.009. Epub 2014 Apr 26.
10
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.美国胸科学会/欧洲呼吸学会官方声明:特发性间质性肺炎的国际多学科分类的更新。
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST.